SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Tanzania president remorseful over internet shutdown on election day - 2Audits of Espresso Types: Which Mix Is for You?
- 3Brazil's former President Jair Bolsonaro seeks house arrest for prison time citing health issues
- 4Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- 5Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- Find the Standards of Powerful Cooperation: Accomplishing Cooperative energy and Coordinated effort
- West Antarctica’s history of rapid melting foretells sudden shifts in continent’s ‘catastrophic’ geology
- From Overpowered to Coordinated: Individual Accounts of Cleaning up
- Don’t let food poisoning crash your Thanksgiving dinner
- Charli xcx recorded original songs for 'Wuthering Heights' — what to know about the new album for Margot Robbie's film
- Guinea-Bissau's coup called a 'sham' by West African political figures
- Nikki Glaser has been testing out Golden Globes jokes. There's one nobody wants to hear
- Golden satellite insulation sparkles during test | Space photo of the day for Dec. 30, 2025
- Executed Iranian nuclear scientist confessed to aiding Israel after torture, threats against mother
